<code id='80BAE9D162'></code><style id='80BAE9D162'></style>
    • <acronym id='80BAE9D162'></acronym>
      <center id='80BAE9D162'><center id='80BAE9D162'><tfoot id='80BAE9D162'></tfoot></center><abbr id='80BAE9D162'><dir id='80BAE9D162'><tfoot id='80BAE9D162'></tfoot><noframes id='80BAE9D162'>

    • <optgroup id='80BAE9D162'><strike id='80BAE9D162'><sup id='80BAE9D162'></sup></strike><code id='80BAE9D162'></code></optgroup>
        1. <b id='80BAE9D162'><label id='80BAE9D162'><select id='80BAE9D162'><dt id='80BAE9D162'><span id='80BAE9D162'></span></dt></select></label></b><u id='80BAE9D162'></u>
          <i id='80BAE9D162'><strike id='80BAE9D162'><tt id='80BAE9D162'><pre id='80BAE9D162'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:28632
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          How to improve immunocompromised access to mAb treatments
          How to improve immunocompromised access to mAb treatments

          Monoclonalantibodiesfightagroupofcoronaviruscellsina3Drendering.AdobeAstheU.S.grappleswiththelasting

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Many breast cancer patients receive more radiation than needed

          KathiKolb,aRhodeIslandphysicaltherapist,saysshe’sfrustratedthatfewerthanhalfofeligiblebreastcancerpa